Medical Analysis

Understanding Des-Gamma-Carboxy Prothrombin (PIVKA-II): A Comprehensive Guide to Clinical Diagnostics and Liver Health

Introduction to PIVKA-II

Des-gamma-carboxy prothrombin (DCP), widely recognized as PIVKA-II (Protein Induced by Vitamin K Absence-II), is a distinct form of factor II prothrombin produced by the liver in the absence of adequate Vitamin K [4, 7]. The underlying biochemical mechanism involves defective gamma-carboxylation, which leads to the production of an abnormal form of the prothrombin molecule [7]. In healthy individuals and those with most common liver diseases, PIVKA-II is typically undetectable in the serum [4, 5]. However, this marker is significantly increased in patients with Acute hepatitis and Hepatocellular Carcinoma (HCC) [4, 5, 10]. Clinical evidence highlights that PIVKA-II can be elevated even in individuals who demonstrate minimal or no increase in Alpha-fetoprotein (AFP) concentrations [2, 8]. Conversely, it is important to note that PIVKA-II shows only rare elevation in cases of chronic hepatitis or cirrhosis [5]. Because PIVKA-II is highly sensitive to Vitamin K antagonists, levels may also rise in individuals with Vitamin K deficiency or those currently undergoing warfarin therapy [7, 10]. Consequently, it serves as a critical potential tumor marker for the early detection and management of HCC [3, 10].

Biochemical Role and Mechanism of PIVKA-II

PIVKA-II is an abnormal prothrombin molecule resulting from an acquired defect in the post-translational carboxylation of the prothrombin precursor within malignant cells [7]. This biomarker has been clinically shown to be released during specific disease processes [4]. The biochemical basis of PIVKA-II involves the transformation of prothrombin precursors, categorized by glutamate (Glu) content, into abnormal structures [7]. In the context of HCC, the presence of specific markers like PIVKA-II and NX-DCP, when compared in a ratio (PIVKA-II/NX-DCP > 1.5), assists clinicians in differentiating malignant tumor progression—specifically regarding tumor size, vascular invasion, and the potential for metastasis—from benign conditions like obstructive jaundice or Vitamin K deficiency caused by dietary or pharmacological antagonists [3, 7, 15].

Indications for Clinical Testing

Physicians typically order a PIVKA-II test when they suspect the following clinical scenarios:

• Diagnosis and screening of Hepatocellular Carcinoma (HCC) [5, 10].

• Patients who present with normal AFP levels but exhibit suspicious nodular lesions in the liver [2, 8].

• High-level clinical suspicion of HCC in the absence of any other diagnostic clues [5].

Principles of PIVKA-II Laboratory Estimation

The detection of PIVKA-II is performed using highly specific diagnostic assays:

• The test utilizes immunoassay-based detection, such as ELISA (Enzyme-Linked Immunosorbent Assay) or Chemiluminescence [4, 7].

• It employs specific antibodies designed to detect abnormal prothrombin molecules [4].

• The test quantifies serum PIVKA-II levels, which are expressed in mAU/mL (milli-arbitrary units per milliliter) [4].

Proper Blood Sample Collection and Storage

To ensure diagnostic accuracy, the following protocols must be strictly followed during sample collection:

• Collect 3.0 ml of blood in an EDTA (Lavender-capped) tube [7].

• Separate the plasma immediately after collection and freeze it [7].

• Send a minimum of 0.5 ml of sample plasma to the laboratory [7].

• It is critical that the sample is not thawed before it reaches the laboratory facility [7].

Reference Ranges and Cutoff Values for PIVKA-II

Comparative Analysis: PIVKA-II vs. AFP (Alpha-fetoprotein)

Advantages of PIVKA-II in Clinical Practice

PIVKA-II offers several distinct advantages for the management of liver disease [4, 5]:

• It demonstrates high specificity for Hepatocellular Carcinoma (HCC) [3, 13].

• It is capable of detecting early-stage HCC cases [3, 8].

• It is highly effective for monitoring treatment response [3, 10].

• It is helpful in the detection of tumor recurrence [10, 12].

• It can be used in combination with AFP to significantly improve diagnostic accuracy [9, 11].

• It reflects tumor aggressiveness and the presence of vascular invasion [3, 15].

• Levels correlate directly with prognosis and the progression of the disease [12, 14].

• It is less affected by benign liver conditions when compared to AFP markers [5, 6].

Clinical Applications and Utility

Clinical Significance and Interpretation

• HCC Diagnosis: It acts as a sensitive early marker that distinguishes HCC from cirrhosis and hepatitis B [3, 5].

• Tumor Aggressiveness: The level of PIVKA-II correlates with tumor size, degree of invasion, and tumor stage [3, 15].

• Prognosis: Elevated levels indicate a poor outcome and aggressive tumor behavior [12, 14].

• Sex Differences: Males typically show higher baseline levels, which must be considered during result interpretation [7].

• Combined Use: Utilizing PIVKA-II alongside AFP improves overall early HCC detection rates [9, 11].

• Liver Function: PIVKA-II levels are often linked to other established markers of liver dysfunction [5, 7].

Prognostic Significance and Cautions

Elevated levels of PIVKA-II are strongly associated with a poor prognosis in patients undergoing various treatment modalities [12, 14]. Clinicians are advised to correlate elevated values cautiously by considering several non-malignant factors, as PIVKA-II levels may rise due to:

• Non-cirrhotic chronic hepatitis B [5].

• Vitamin K deficiency, usage of warfarin/Vitamin K antagonists, or transplant rejection [7, 10].

• Primary gastric adenocarcinoma [7].

• Intestinal flora imbalance, renal failure, inflammatory bowel disease, lack of nutrition, and alcoholic liver disease [7].

Limitations of PIVKA-II Testing

• It can be elevated in cases of Vitamin K deficiency, leading to potential false-positive results [7, 10].

• Increased levels are consistently found in patients taking warfarin or other Vitamin K antagonists [7].

• Levels may rise in non-malignant liver diseases, including cirrhosis or hepatitis [6].

• Assay methods are not yet fully standardized across different laboratory facilities [7].

• It cannot distinguish between different stages or specific subtypes of HCC with absolute precision [7].

• It should not be utilized as the sole diagnostic marker; results require correlation with imaging studies and AFP levels [3, 11].

• False-negative results may occur in cases of small or early-stage tumors that have not yet developed vascular invasion [3, 8].

For Non-Medicos: Understanding PIVKA-II and Your Liver Health

What is PIVKA-II?

PIVKA-II is a special protein that the liver produces when it is not getting enough Vitamin K [4, 7]. Doctors use this test as a “warning sign” to help detect liver problems, specifically Hepatocellular Carcinoma (HCC), which is the most common type of liver cancer [5, 10]. Think of it as a tumor marker—a substance in your blood that can signal the presence or activity of a tumor [4, 7].

Why Do Doctors Use This Test?

Your doctor may order a PIVKA-II test if:

• They are screening for liver cancer, especially in patients at high risk (like those with chronic hepatitis) [5, 11].

• You have a liver “nodule” or spot that needs further investigation [8].

• They want a more accurate picture than AFP alone can provide [9, 11].

What Your Results Might Mean

• Normal Levels: Generally indicate that your liver is functioning as expected regarding this protein [5].

• High Levels: Could suggest the presence of liver cancer, but they can also be caused by other things [7, 10]. Because PIVKA-II is sensitive to Vitamin K, if you are taking blood-thinning medications like warfarin, your levels might be artificially high [7]. Other factors like severe nutritional issues, kidney failure, or certain inflammatory conditions can also cause this level to rise [7].

Important Things for Patients to Know

• Tell Your Doctor: Always inform your healthcare provider if you are taking blood thinners (like warfarin) or have known Vitamin K deficiency before getting this test [7].

• It’s Not a Standalone Test: A high PIVKA-II level does not automatically mean you have cancer [7]. Doctors almost always use this test in combination with imaging (like an ultrasound or CT scan) and other blood tests like AFP to get the full picture [3, 11].

• Follow-up: If your levels are elevated, your doctor will guide you through the next steps, which may include further imaging or a referral to a liver specialist to understand the exact cause [5, 11].

References:

• Durazo, F. A., Blatt, L. M., Corey, W. G., Saab, S., Tong, M. J., Ahmadi, A., … & Han, S. H. (2008). Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 fraction: serological biomarkers for hepatocellular carcinoma and evaluation of the cancer of the liver Italian program score. Journal of Gastroenterology and Hepatology, 23(10), 1541-1548.

• Marrero, J. A., Feng, Z., Wang, Y., Nguyen, M. H., Befeler, A. S., Roberts, L. R., … & Lok, A. S. (2009). Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology, 137(1), 110-118.

• Poté, N., Cauchy, F., Albuquerque, M., Voitot, H., Belghiti, J., Castera, L., … & Bedossa, P. (2015). Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. Journal of Hepatology, 62(4), 848-854.

• Sassa, T., Kumada, T., Kono, D., Toyoda, H., & Nakano, I. (2014). Des-γ-carboxy prothrombin (DCP) as a novel biomarker for hepatocellular carcinoma: A review. International Journal of Hepatology, 2014, 563567.

• Song, P., Feng, X., Inagaki, Y., Song, G., & Zhang, Y. (2015). Clinical utility of des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma. Hepatology International, 9(1), 57-65.

• Volk, M. L., Hernandez, J. C., Su, G. L., Lok, A. S., & Marrero, J. A. (2009). Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, AFP-L3, and des-gamma-carboxyprothrombin. Cancer Biomarkers, 5(2-3), 79-87.

• Tartaglione, S., et al. (2024). Biochemical basis of PIVKA-II in liver disease: Diagnostic and prognostic implications. Heliyon, 10(6), e26653.

• Seo, S. I., Kim, H. S., Kim, W. J., Tak, W. Y., Jang, S. Y., Cho, H. C., … & Lee, S. K. (2015). Diagnostic value of PIVKA-II and alpha-fetoprotein in patients with small hepatocellular carcinoma. Clinical and Molecular Hepatology, 21(1), 39-46.

• Bei, C., et al. (2019). Combined use of alpha-fetoprotein and des-gamma-carboxyprothrombin for the diagnosis of hepatocellular carcinoma: A meta-analysis. Journal of Cancer, 10(9), 2095-2107.

• Zhu, X. D., & Sun, H. C. (2019). Clinical value of PIVKA-II in hepatocellular carcinoma. Journal of Clinical and Translational Hepatology, 7(2), 178-184.

• Chaiteerakij, R., Addissie, B. D., Roberts, L. R., & Stadheim, L. (2015). Biomarkers for hepatocellular carcinoma. Advances in Clinical Chemistry, 69, 1-40.

• Shirabe, K., Itoh, S., Yoshizumi, T., Soejima, Y., Ikegami, T., Oshiro, H., … & Maehara, Y. (2010). The prognostic value of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Journal of Gastroenterology, 45(4), 434-441.

• Li, C., Zhang, H., Lu, H., & Feng, C. (2016). The diagnostic value of des-gamma-carboxyprothrombin for hepatocellular carcinoma: a meta-analysis. Tumor Biology, 37(1), 387-393.

• Utsunomiya, T., Shimada, M., Kudo, M., Ichida, T., Matsui, O., Izumi, N., … & Liver Cancer Study Group of Japan. (2015). A comparison of the prognostic value of des-gamma-carboxy prothrombin and alpha-fetoprotein in patients with hepatocellular carcinoma. Journal of Gastroenterology, 50(2), 226-234.

• Yang, W., Li, J., & Wang, Y. (2019). Des-gamma-carboxyprothrombin as a predictor of microvascular invasion in hepatocellular carcinoma: A systematic review and meta-analysis. Hepatology Research, 49(12), 1435-1445.

FAQ’s:

• What is PIVKA-II?
  It is an abnormal prothrombin protein produced by the liver in the absence of Vitamin K.

• Why is the test performed?
  Doctors use it to screen for and diagnose hepatocellular carcinoma, a common type of liver cancer.

• How does PIVKA-II indicate cancer?
  It is released by malignant liver cells due to an acquired defect in protein modification processes.

• Is it better than AFP?
  It is often more sensitive than AFP and can detect liver cancer when AFP levels are normal.

• Does warfarin affect test results?
  Yes, warfarin and other Vitamin K antagonists can cause artificially high levels of PIVKA-II in blood.

• How is the sample collected?
  A blood sample is collected in an EDTA tube, and plasma must be separated and frozen immediately.

• Can diet affect PIVKA-II?
  Yes, poor nutrition or Vitamin K deficiency can lead to elevated PIVKA-II levels, causing false positives.

• What does a high result mean?
  It indicates possible liver cancer, but requires further imaging and correlation with other blood markers.

• Is one test diagnostic?
  No, it should not be used as a sole marker; clinical correlation with imaging is strictly required.

• How is PIVKA-II measured?
  It is quantified using immunoassay techniques like ELISA or chemiluminescence, expressed in milli-arbitrary units.

Related Diagnostic Tests

• Liver Function Test (LFT)

• Prothrombin Time (PT/INR)

• CA 19.9